ArticleMolecular and cellular biochemistry2012
Activation of PPARδ up-regulates the expression of insulin gene transcription factor MafA and ameliorates glucose-induced insulin secretion impaired by palmitate.
Article in Molecular and cellular biochemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 11 citations in OpenAlex.
- MafA Regulation in β-Cells: From Transcriptional to Post-Translational Mechanisms.Biomolecules · 2022Review
- PPARs and the Development of Type 1 Diabetes.PPAR research · 2020Review
- Prolactin and oleic acid synergistically stimulate β-cell proliferation and growth in rat islets.Islets · 2017Article
- Nuclear receptors and the Warburg effect in cancer.International journal of cancer · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PPARδ, a member of the peroxisome proliferator-activated receptor superfamily, plays a key role in the transcriptional regulation of genes involved in cellular lipid and energy metabolism. Therefore, PPARδ may represent a new target for the treatment of obesity, hyperlipidemia, and type 2 diabetes. MafA is a β-cell-specific and glucose-regulated transcriptional activator for insulin gene expression and plays a crucial role in pancreas development, β-cell differentiation as well as maintenance of β-cell function. However, little is known about how PPARδ regulates MafA and ameliorates glucose-stimulated insulin secretion impaired by free fatty acids (FFA). In the present study, we evaluated the basal insulin secretion (BIS), glucose-stimulated insulin secretion (GSIS), and insulin secretion index (ISI) of INS-1E cells that were cultured in media supplemented with or without 0.5 mM palmitate and treated with or without a PPARδ agonist (GW501516) or PPARδ siRNA. The expression of MafA, glucose transportor-2 (GLUT2), and insulin was found to be up-regulated in cells treated with GW501516. Finally, analysis of the level of JNK phosphorylation revealed that activated PPARδ could inhibit the activation of JNK and increase the expression of MafA. Accordingly, the insulin secretion dysfunction in lipotoxic INS-1E cells was improved. Collectively, these results demonstrate that activation of PPARδ improves insulin secretion impaired by palmitate and plays a role in the JNK-MafA-GLUT2 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.